Pacific Biosciences of California, Inc. $PACB Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lowered its position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) by 17.5% in the third quarter, Holdings Channel reports. The fund owned 4,955,567 shares of the biotechnology company’s stock after selling 1,054,148 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Pacific Biosciences of California were worth $11,745,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of PACB. Mirae Asset Global Investments Co. Ltd. purchased a new position in Pacific Biosciences of California in the third quarter valued at $38,000. Choreo LLC purchased a new stake in shares of Pacific Biosciences of California during the 3rd quarter worth approximately $27,000. Interchange Capital Partners LLC purchased a new stake in shares of Pacific Biosciences of California during the 3rd quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Pacific Biosciences of California by 14.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 56,714 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 7,282 shares in the last quarter. Finally, AdvisorNet Financial Inc boosted its holdings in shares of Pacific Biosciences of California by 17.2% in the 3rd quarter. AdvisorNet Financial Inc now owns 178,288 shares of the biotechnology company’s stock valued at $423,000 after buying an additional 26,166 shares in the last quarter.

More Pacific Biosciences of California News

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: PacBio reported third-quarter revenue of $40.56 million, above the $39.31 million consensus, and a loss of $0.11 per share, narrower than the expected $0.13 loss. Coverage also highlighted clinical adoption and AI partnerships as sources of growth. Zacks Q3 results Q3 deep dive
• Positive Sentiment: Piper Sandler reaffirmed its Neutral rating but raised its price target to $3 from $2, indicating a more favorable valuation view. Piper Sandler rating
• Neutral Sentiment: The company announced CFO changes; the report provided no further detail on the transition’s expected impact. CFO changes
• Negative Sentiment: Management narrowed its 2026 revenue guidance to $155 million–$160 million. Analysts also pointed to falling gross margins and substantial cash burn, which raises concerns about the company’s financial position despite its target of cash-flow breakeven in 2028. Revenue guidance and breakeven target Q3 outlook analysis
• Negative Sentiment: Barclays lifted its price target to $2 from $1.25 but maintained an Underweight rating, signaling continued caution about the shares. Barclays rating

Pacific Biosciences of California Stock Performance

PACB traded down $0.17 on Friday, reaching $2.26. 9,531,021 shares of the company’s stock were exchanged, compared to its average volume of 15,198,901. Pacific Biosciences of California, Inc. has a twelve month low of $1.07 and a twelve month high of $3.43. The company’s 50 day moving average is $1.93 and its 200-day moving average is $1.62. The company has a market cap of $702.48 million, a price-to-earnings ratio of -5.38 and a beta of 2.21.

Pacific Biosciences of California (NASDAQ:PACB) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. Pacific Biosciences of California had a negative net margin of 82.49% and a negative return on equity of 5,752.12%. The firm had revenue of $40.56 million for the quarter, compared to analysts’ expectations of $39.31 million. Sell-side analysts forecast that Pacific Biosciences of California, Inc. will post -0.52 EPS for the current year.

Wall Street Analysts Forecast Growth

PACB has been the subject of a number of research reports. UBS Group began coverage on shares of Pacific Biosciences of California in a report on Wednesday, September 9th. They issued a “neutral” rating and a $1.35 target price for the company. Weiss Ratings upgraded Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, October 13th. Barclays raised their price objective on shares of Pacific Biosciences of California from $1.25 to $2.00 and gave the stock an “underweight” rating in a research note on Thursday. Wall Street Zen raised shares of Pacific Biosciences of California from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Piper Sandler reiterated a “neutral” rating and set a $3.00 target price (up from $2.00) on shares of Pacific Biosciences of California in a research report on Thursday. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Pacific Biosciences of California currently has an average rating of “Reduce” and a consensus price target of $2.09.

Insider Buying and Selling at Pacific Biosciences of California

In related news, insider Mark Van Oene sold 26,911 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1.13, for a total value of $30,409.43. Following the completion of the sale, the insider directly owned 2,705,853 shares in the company, valued at approximately $3,057,613.89. This represents a 0.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James Gibson, II sold 661,815 shares of the company’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $3.11, for a total value of $2,058,244.65. Following the completion of the sale, the insider directly owned 1,083,848 shares of the company’s stock, valued at $3,370,767.28. The trade was a 37.91% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.70% of the company’s stock.

Pacific Biosciences of California Profile

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.